Monday, May 16, 2016

Pulseless Electrical Activity Demystified

Pulseless Electrical Activity by Amal Mattu (From Resuscitation 2015) 





This video is also available on youtube. 

More thoughts on PEA:
http://rebelem.com/a-new-pulseless-electrical-activity-algorithm/
http://adelaideemergencyphysicians.com/2014/08/a-new-pea-diagnostic-algorithm-ecg-and-ultrasound/

Monday, May 9, 2016

TakoTsubo Cardiomyopathy

Introduction

TakoTsubo Cardiomyopathy (TTC), also known as broken-heart syndrome, apical ballooning syndrome or stress-induced cardiomyopathy. It is a reversible cardiomyopathy characterised by transient systolic ventricular dysfunction with a clinical presentation indistinguishable from acute myocardial infarction but in the absence of significant coronary artery obstruction. This condition is frequently precipitated by sudden, stressful emotional events, occasionally due to physiologic stress such as sepsis, non-cardiac surgery, and subarachnoid hemorrhage.
The term "Takotsubo"  was coined to describe the unusual shape of the left ventricular during systole. Typically, the mid to apical segments of the left ventricle are akinetic and the spared, basal walls exhibit compensatory hypercontractility. Takotsubo is a pot with round base and narrow neck used in Japan for trapping octopuses and has a similar appearance to this apical ballooning. 




TTC occurs most commonly in postmenopausal women and has a very good prognosis. Acutely, patients are often critically ill with heart failure, arrhythmias, shock, LVOT obstruction, thromboembolism but symptoms resolve quickly and death is rare.

Pathophysiology 
The pathophysiologic basis of TTC has not been conclusively determined but several mechanisms have been proposed. The underlying histopathological findings on myocardial biopsy are distinctly different from those of coagulation necrosis seen in typical atherosclerotic epicardial artery occlusion and myocardial infarction. 
  • Catecholamine overload and myocardial stunning 
  • Multi-vessel coronary artery spasm with resultant ischemia and stunned myocardium 
  • Spontaneously aborted myocardial infarction 
  • Microvascular dysfunction and myocarditis


Clinical presentation 
TTC has been reported to account for 1-3% of all acute coronary cases. About 90% of cases reported are in post-menopausal women ages 58-75 years old.  The clinical presentation of TTC is often identical to acute myocardial infarction (AMI). Most patients with takotsubo cardiomyopathy present with typical anginal chest pain, dyspnea, ischemic changes on electrocardiogram (ECG), and elevated cardiac markers.  Emotional stress, such as news of the death of a family member, divorce, or public speaking, is implicated as the trigger in approximately two-thirds of patients. 

ECG changes and cardiac biomarkers 
The most common abnormality on the ECG is ST elevation and T-wave inversion in the precordial leads. However, there may be some population differences in presenting signs and specific ECG changes should be considered suggestive but not diagnostic of TTC. Modest elevation of cardiac biomarkers is often observed in TTC.

ECG Image (TTC) from LIFTL

Diagnosis 
Due to the dramatic clinical presentation and high suspicion for acute myocardial infarction, most patients undergo emergent coronary angiography. Typical findings in TTC are normal epicardial coronaries, mild non-obstructive atherosclerosis, or rarely coexistent coronary artery disease. Therefore, TTC is a diagnosis of exclusion which can only be made after coronary angiography. It should be on the differential diagnosis in any post-menopausal women over 50 years old presenting with chest pain and ischemic ECG changes particularly in the setting of emotional stress. Furthermore it should also be considered in critically ill patients with sudden hemodynamic compromise and/or heart failure. 

Mayo Clinic proposed diagnostic criteria in 2004 for TTC which includes four components:
(1) Transient hypokinesis, akinesis, or dyskinesis of the left ventricular mid seg- ments with or without apical involvement; the regional wall motion abnormalities extend beyond a single epicardial vascular distribution; a stressful trigger is often, but not always present 
(2) Absence of obstructive CAD or angiographic evidence of acute plaque rupture 
(3) New electrocardiographic abnormalities (either ST-segment elevation and/or T wave inversion) or modest elevation in cardiac troponin 
(4) Absence of pheochromocytoma and myocarditis

Cardiac imaging 
Ventriculography reveals apical ballooning, with characteristic sparing of the basal segments and akinesis of the mid and apical left ventricle. However, variants of this pattern have been described. In patients with typical TTC, the wall motion abnormality usually extends beyond the distribution of a single coronary artery. 
Echocardiography can detect and measure the degree of left ventricular outflow (LVOT) obstruction and associated systolic motion of the anterior mitral valve and significant mitral regurgitation. 
LVOT obstruction is reported to occur in 25% patients and can have a major impact on acute management. In patients with hemodynamic compromise and shock, inotropes would worsen this situation and betablockers and pure vasopressor pharmacologic or mechanical support may be needed. The typical findings on cardiac MRI include the absence of delayed gadolinium hyperenhancement. This is specific to TTC and can help differentiate it from myocarditis and acute myocardial infarction in which delayed hyperenhancement is present.

Treatment 
Takotsubo cardiomyopathy has an excellent prognosis, with full and early recovery in virtually all patients. The majority of patients have normalization of LVEF within a week and all patients by 4-8 weeks. Long-term survival is similar to the general population. 
  • The goals of treatment are usually conservative, supportive care. The therapy is guided by the patient’s clinical presentation and hemodynamic status. Despite the possible causal role of catecholamines in the disorder, patients who present in cardiogenic shock, and in the absence of LVOT obstruction, may be treated with inotropes. 
  • Alternatively patients may derive further benefit from IABP and VADs. 
  • If LVOT obstruction is present with cardiogenic shock, inotropes should be avoided and phenylphrine is the pressor agent of choice often combined with betablockade.
  • Anticoagulation is reserved for those with ventricular thrombus or evidence of embolic events. 


Take Home
  • Takotsubo cardiomyopathy is an acquired cardiomyopathy which is a differential diagnosis of acute coronary syndrome. 
  • It is characterized by transient systolic ventricular dysfunction with regional wall motion abnormalities beyond a single vascular territory in the absence of significant epicardial coronary artery obstruction. 
  • Acute emotional/ physical stressor immediately preceding the acute coronary syndrome is a common presentation. Catecholamine excess and cardiotoxicity is the most likely underlying mechanisms.
  • Supportive treatment is the mainstay of therapy.

References:
  1. Kurisu S, Kihara Y. Clinical management of takotsubo cardiomyopathy. Circ J. 2014. 78 (7):1559-66. 
  2. Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J. 2008 Mar. 155(3):408-17.
  3. Bybee KA, Kara T, Prasad A, et al. Systematic review: transient left ventricular apical ballooning: a syndrome that mimics ST-segment elevation myocardial infarction. Ann Intern Med. 2004 Dec 7. 141(11):858-65.
  4. Merchant EE, Johnson SW, Nguyen P, Kang C, Mallon WK. Takotsubo cardiomyopathy: a case series and review of the literature. WestJEM. 2008. 9:104-11.

Monday, May 2, 2016

Brugada Syndrome: Rapid Review

Introduction

Brugada Syndrome was first described by Pedro and Josep Brugada in 1992 in eight otherwise healthy patients with sudden and aborted cardiac death, in whom they found “right bundle branch block and persistent ST segment elevation in leads V1 to V3”. It’s incidence seems to be particularly high in Southeast Asia where it had been previously described as Sudden Unexplained Nocturnal Death Syndrome (SUNDS), The condition is also believed to be one of the potential causes of sudden infant death syndrome and sudden cardiac death in young children. 

The condition is supposed to be due to a cardiac sodium channel mutation. ECG changes can be transient with Brugada syndrome and can also be unmasked or augmented by severe, schema and medications. 


Check out this short video on Brugada Syndrome, by the legendary "Amal Mattu" 

Different patterns of STE in Brugada Syndrome:

1) Coved: a coved-type (straight or convex upward) terminating in an inverted T-wave, more predictive of arrhythmic events.
2) Saddle: Concave upward



Diagnostic Criteria:

This ECG abnormality must be associated with one of the following clinical criteria to make the diagnosis:



  • Documented ventricular fibrillation or polymorphic ventricular tachycardia
  • Family history of sudden cardiac death at <45 years old 
  • Coved-type ECGs in family members
  • Inducibility of VT with programmed electrical stimulation 
  • Syncope
  • Nocturnal agonal respiration
Definite Treatment

Pharmacological treatment does not protect against recurrent events and implantation of an cardiac defibrillators is the only proven effective treatment in preventing sudden death in patients with the Brugada syndrome.


The term “Brugada Syndrome” is used when the Brugada ECG is accompanied by symptoms of syncope or cardiac arrest.


Take Home



  • Knowledge of Brugada ECG pattern is paramount for Emergency Physicians.
  • Patients with suspected Brugada Syndrome require an early cardiology or electrophysiology opinion. 
  • Definite treatment is implantation of a defibrillator to prevent death from sudden ventricular arrhythmia.  


Further Reading:


  1. http://lifeinthefastlane.com/what-is-brugada-syndrome/
  2. https://www.youtube.com/watch?v=0pbGlhefScg (Part 2)
  3. http://www.medscape.com/viewarticle/828939

Monday, April 25, 2016

Proton Pump Inhibitors and Anti-emetic Cocktail - A remedy for all

A blend of Proton Pump Inhibitor and anti emetics is something that a bulk of patients get, sometimes without a reason. I think it is time to step back and always question ourselves prior to ordering these medications. More importantly, we need to get rid of the thought that pushes us to prescribe thinking that "if there is no benefit, they are probably not going to hurt". Let us look at some possible downsides of these drugs. 


Proton Pump Inhibitors

They are used for a myriad of concerns such as headache, vomiting, nausea, abdominal pain (regardless of presumed etiology), eradicate H. Pylori, ZE Syndrome, gastroenteritis, GERD and so on.. While a single dose may not have much side effects but in the long run, there are potential downsides that might accompany these medications. In addition, these are freely available as over the counter preparations and therefore, have the possibility of being misused. 

Possible Adverse Effects with long term use (other than GI Distress and Headache)

1. Hypocalcemia, Osteoporosis and Fractures Probably because dietary calcium absorption is dependent upon an acidic environment in the gut.

2. Hypomagnesemia (May present as arrhythmias)

3. Anemia (B12 and Iron deficiency)
PPIs may also affect vitamin B12 levels because the body can’t absorb the vitamin without stomach acid to uncouple the vitamin from protein in food. 
It is unlikely that patients with normal iron stores will develop iron deficiency anemia from PPI use alone. However, patients with low baseline iron stores may be more susceptible to further iron depletion with concurrent PPI therapy.

4. Increased risk of infections (Pneumonia and Clostridium Difficle)
PPIs blunt the gastric acid secretion that act as a defense mechanism against enteric bacteria. Increased gastric pH during PPI use allows for colonization of opportunistic microbes) 

5. Alters the composition of gut flora 

6. Interact with Clopdrogel (click here to read more on this interaction)
PPI therapy in combination with clopidogrel (Plavix) use may increase the risk of cardiac events.



Ondansetron (AKA Emeset, Zofer, Zofran)

It is a 5HT3 receptor antagonist that is frequently used for Postoperative and Chemo  Induced Nausea Vomiting , also prescribed for N&V in general and gastroenteritis. It is metabolised by liver.


Concerning Adverse Effects
  1. QT prolongation
  2. Headache, Dizziness, Fever 
  3. Rash, Bronchospasm
  4. Diarrhoea/Constipation
  5. Serotonin Syndrome (with concomitant use of serotonergic meds)


References:


1  Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56(9):1291–1295.
2  Ito T, Jensen RT (2010). "Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium". Current Gastroenterology Reports 12(6): 448–57. 
3  Focks JJ, Brouwer MA, van Oijen MG, Lanas A, Bhatt DL, Verheugt FW (2013). "Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review". Heart 99(8): 520–7. 
4   Cardoso RN, Benjo AM, DiNicolantonio JJ, Garcia DC, Macedo FY, El-Hayek G, et al. (2015). "Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis". Open Heart 2 (1): e000248. 
5   Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA (2015). "Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis". PLoS ONE 10 (6): e0128004. 
6  Corleto VD et al. Proton pump inhibitor therapy and potential long-term harm. Current Opinion in Endocrinology, Diabetes and Obesity. 2014 February;21(1):3-8. doi:10.1097/MED.0000000000000031 PMID 24310148
7   US Food and Drug Administration. (2012). FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran). Retrieved from http://www.fda.gov/Drugs/DrugSafety/ucm310190.htm
8  Gollapudy, Suneeta, Vikram Kumar, and M. Saeed Dhamee. "A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion." Journal of clinical anesthesia 24.3 (2012): 251-252.